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ABSTRACT
Over-expression of PDGF receptors (PDGFRs) has been previously implicated 
in high-risk medulloblastoma (MB) pathogenesis. However, the exact biological 
functions of PDGFRα and PDGFRβ signaling in MB biology remain poorly understood. 
Here, we report the subgroup specific expression of PDGFRα and PDGFRβ and their 
associated biological pathways in MB tumors. c-MYC, a downstream target of PDGFRβ 
but not PDGFRα, is involved in PDGFRβ signaling associated with cell proliferation, 
cell death, and invasion. Concurrent inhibition of PDGFRβ and c-MYC blocks MB cell 
proliferation and migration synergistically. Integrated analysis of miRNA and miRNA 
targets regulated by both PDGFRβ and c-MYC reveals that increased expression of 
JAG2, a target of miR-1280, is associated with high metastatic dissemination at 
diagnosis and a poor outcome in MB patients. Our study may resolve the controversy 
on the role of PDGFRs in MB and unveils JAG2 as a key downstream effector of a 
PDGFRβ-driven signaling cascade and a potential therapeutic target.
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INTRODUCTION
Medulloblastoma (MB) is the most frequently 
diagnosed malignant pediatric brain tumor. Approximately 
30% of patients with MB are resistant to therapies and 
prone to develop metastasis [1–9]. Several earlier studies 
have shown that over-expression and/or over-activation of 
certain genes such as PDGFRs and c-MYC in the tumor 
tissues of MB patients are correlated with an aggressive 
tumor phenotype and poor prognosis [10–14].
The activation of PDGFR signaling initiates events 
that culminate in cell proliferation, survival, and migration 
[15–19]. A plethora of evidence shows that the MB cells 
with abnormal PDGFR signaling, attributable to the over-
expression of PDGFRs or their ligands [11, 12, 20, 21], 
or mutation in PDGFRα, are linked to metastatic disease 
[19]. PDGFRα was initially found to be highly expressed 
in metastatic MBs, and it was further proposed to be a 
therapeutic target for metastatic MB based on the results 
that metastatic MB cells lost their metastatic phenotypes 
(reduced capabilities on adhesion and migration in vitro) 
upon blockade of PDGFRα signaling using a PDGFRα-
neutralizing antibody and a MAP2K1/2 inhibitor [11, 20]. 
These results led to the proposal by MacDonald and 
coworkers that PDGFRα is a bona fide therapeutic target 
for metastatic MB [11, 20]. However, in subsequent 
studies, the PDGFRα probe-set used in the microarray 
analysis by MacDonald and his coworkers was shown 
to detect PDGFRβ [12]. The controversy regarding the 
roles of PDGFRα and PDGFRβ in MB has continued, 
i.e., PDGFRα was deregulated in both the primary and 
metastatic tumors in a sleeping beauty mouse model 
of MB [22]. Taking earlier and more recent results as a 
whole, it is evident that the controversy lingers and the 
dispute remains unresolved.
MB tumors are highly heterogeneous. Based on 
their molecular and clinical characteristics, at least four 
subgroups, WNT, SHH, Group 3, and Group 4 exist [14, 
23–33]. Among these subgroups, the preferential survival 
rates of MB patients from good to poor are: WNT> 
SHH / Group 4>Group 3 [29, 34]; however, metastatic 
MBs are found in all subgroups. As yet, the role of 
PDGFR-mediated signaling has not been examined in 
the context of MB subgroups, and whether PDGFRα and 
PDGFRβ could initiate convergent or divergent events in 
MB remains to be determined.
c-MYC is a proto-oncogene encoding a transcription 
factor that controls multiple cellular events such as 
proliferation [35, 36], cell cycle [37–39], and apoptosis 
[40–43] by regulating the expression of its target genes. 
Over-expression of c-MYC promotes tumorigenesis while 
inhibition of c-MYC reduces tumor growth in vitro and 
in vivo [10, 13]. It has been shown that over-expression 
or oncogenic activation of c-MYC in MB may be also 
linked to an aggressive phenotype, and MB patients with 
elevated levels of c-MYC often have poor outcomes 
[10, 13, 14, 44, 45]. Inhibition of c-MYC using either 
siRNA or pharmacological intervention has been shown 
to limit tumor growth in vitro [43, 46–49]. These studies 
suggest that c-MYC plays a crucial role in MB biology.
Notch signaling, one of major determinants 
regulating cell differentiation [50], is a critical pathway 
regulating stem cell differentiation and tumor progression 
[51–54]. Abnormal activation of Notch pathway was 
demonstrated to induce tumor formation [50, 55]. A few 
studies indicate that Notch signaling may play a role in 
MB progression [53]; however, whether the regulation of 
Notch signaling by PDGFR in MB has not been reported.
In this study, we analyzed the expression levels of 
PDGFRα and PDGFRβ in primary MB for their associated 
gene signatures. We further used MB cells to elucidate 
their individual functions on cell proliferation, migration, 
and invasion. Moreover, by combining miRNA profiling 
with bioinformatics-aided target prediction complemented 
by experimental validation, we identified a potential 
novel therapeutic target, JAG2, which appears to act as 
a downstream target of the PDGFRβ-c-MYC signaling 
pathway. We further determined the expression levels of 
JAG2 in MB tissues for its prognostic value.
RESULTS
Expression of PDGFRα and PDGFRβ is 
associated with different prognosis in patients 
with MB
To define the biological roles of PDGFRs in MB, 
we analyzed the subgroup dependent mRNA levels 
of PDGFRα and PDGFRβ in two independent, non-
overlapping gene expression profiling data sets [29, 56, 
57]. As shown in Figure 1A, 1B, 1C, 1D and Table S1, the 
expression of PDGFRα was elevated in WNT and SHH 
subgroups (p < 0.001), while high levels of PDGFRβ 
were found in a subset of tumors from all subgroups, 
particularly high in SHH tumors (p < 0.001). We further 
analyzed the expression patterns in 3 sets of data and 
obtained similar results (Figure S1) [32, 58, 59]. Our 
previous studies revealed that patient with WNT MB has 
a better outcome than the one with SHH / Group 4 and 
Group 3 MBs [29, 34]. Our results suggest that expression 
of PDGFRα and PDGFRβ may be associated with the 
differences in prognosis.
We next searched for the molecular signatures of 
PDGFRα, PDGFRβ, and c-MYC in MBs using the R2 
software (http://r2.amc.nl) by assessing the correlations of 
genes in major pathways with cellular functions in five 
cohorts of MBs previously determined by microarray from 
at least more than 45 samples containing all 4 subgroups 
of clinical MBs [29, 32, 33, 59, 60]. By analyzing the 
KEGG (Kyoto Encyclopedia of Genes and Genomes) 
pathway annotation in these data sets, we revealed that 
several pathways were significantly associated with 
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PDGFRα and PDGFRβ expression, respectively, in 
the five separate tumor cohorts. As shown in Table 1, 
Supplemental Tables S2, S3, both the expression of 
PDGFRα and PDGFRβ in MB tumors was associated 
with signatures related to ‘ECM receptor interaction’, 
‘Focal adhesion’, and ‘Pathways in cancer’. Notably, 
distinct signaling pathways for PDGFRα and PDGFRβ 
were also identified. For instance, ‘Wnt signaling 
pathway’, ‘Hedgehog signaling pathway’, and ‘Hippo 
signaling pathway’ were only associated with PDGFRα 
expression; while ‘Cell adhesion molecules_CAMs’, 
‘Apoptosis’, ‘NFĸB signaling pathway’, and ‘Cytokine_
cytokine receptor interaction’ were only associated with 
PDGFRβ expression. These data suggest that PDGFRs 
regulate distinct cellular functions in MB including cell 
proliferation, cell death, and cellular mobility.
Figure 1: The subgroup specific expression of PDGFRα and PDGFRβ in primary MB. (A) Boxplot showing PDGFRα 
expression in normal adult cerebellar samples and MB subgroups based on the Boston cohort (n = 199). (B) Relative expression of 
PDGFRα as a log2-ratio compared to a pool of normal cerebellar samples according to MB subgroups based on the Heidelberg cohort 
(n = 64). (C) Boxplot showing PDGFRβ expression in normal adult cerebellar samples and MB subgroups based on the Boston cohort. 
(D) Relative expression of PDGFRβ as a log2-ratio compared to a pool of normal cerebellar samples according to MB subgroups based on 
the Heidelberg cohort.
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The frequency of pathways found in 5 sets of 
data are marked as following: 2 out of 5:  3 out of 5:  4 out of 5:  5 out of 5: 
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PDGFRβ instead of PDGFRα promotes MB 
progression
The distinct expression patterns of PDGFRα 
and PDGFRβ in MB subgroups and the association of 
distinct signaling pathways of PDGFRs in MBs led us 
to hypothesize that PDGFRα and PDGFRβ have distinct 
roles in MB progression. To functionally characterize 
the biological impact of these signaling events induced 
by the two PDGFRs, we assessed the effects on Daoy 
and D283 MB cells in cell proliferation and cell death 
in response to siRNA knockdown either PDGFRα or 
PDGFRβ. PDGFRβ knockdown resulted in decreased 
cell proliferation and increased cell death (p < 0.01; 
p < 0.01, respectively), while treatment with PDGFRα 
siRNA showed an increased cell proliferation and 
reduced cell death (p < 0.05; p < 0.05, respectively) 
(Figure 2A, 2B) in both Daoy and D283 cells. We also 
checked cell invasion under conditions of PDGFRα and 
PDGFRβ blockade using their respective neutralizing 
antibodies. We observed that interference with PDGFRα 
signaling promoted invasion, while disrupted PDGFRβ 
signaling inhibited invasion in Daoy cells (Figure 2C, 
S2). These results lead to the conclusion that PDGFRβ 
but not PDGFRα is a critical element to promote 
aggressive behavior of MBs. To understand the distinct 
cellular functions elicited by PDGFRα and PDGFRβ in 
MB cells, we further analyzed the expression of c-MYC, 
a previously defined PDGF response gene as a key 
determinant involved in cell proliferation [61–63]. In 
cells featuring siRNA-mediated knockdown of PDGFRα 
or PDGFRβ, we found that c-MYC expression was 
reduced in PDGFRβ siRNA-treated but not PDGFRα 
siRNA-treated cells, suggesting that c-MYC may be a 
downstream target of PDGFRβ partially contributing 
to the differential effects initiated by PDGFRα and 
PDGFRβ (Figure 2D, 2E).
Co-targeting PDGFRβ and c-MYC expression 
reduces MB cell proliferation
Analysis of MBs using high-resolution DNA copy 
number profiling showed that c-MYC amplification 
was mainly found in Group 3 MBs (25% of MBs) [60]; 
while Grotzer et al. demonstrated by RT-PCR using a 
cohort of 26 MBs that all MBs express c-MYC [44]. 
We thus also analyzed the genes in the pathways co-
expressed with c-MYC in the 5 data sets [29, 32, 33, 
Figure 2: PDGFRs have distinct cellular functions and PDGFRβ regulates c-MYC. (A) Effect of siRNA-mediated knockdown 
of PDGFRα and PDGFRβ in MB cells on cell proliferation. After 48 h of transfection, the rates of cell proliferation were determined using 
MTS assay; (B) siRNA-mediated knockdown of PDGFRα and PDGFRβ in MB cells on cell death. PDGFRα and PDGFRβ in MB cells 
were knocked down using siRNA and the rate of cell death was determined by LDH at 48 h; (C) Daoy cell migration/invasion was assessed 
in the presence of a control antibody, PDGFR neutralizing antibodies (mouse IgG as control for anti-PDGFRα, goat IgG as control for anti-
PDGFRβ) as described in the Materials and Methods. *p < 0.05, **p < 0.01 (paired Student’s t-test, sample vs. control); (D) PDGFRα and 
PDGFRβ signaling differentially regulates the expression of c-MYC in MB cells. PDGFRα and PDGFRβ in MB cells were knocked down 
using siRNAs. After 48 h of siRNA transfection, cells were harvested as protein lysates for Western blotting analysis; (E) The relative levels 
of PDGFRs and c-MYC in response to the siRNA treatments were calculated from the gel images of (D).
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59, 60] and our data suggest that c-MYC and PDGFRβ 
activate distinct signaling pathways in MBs (Table 1, 
Supplemental Tables S3, S4). Based on previous 
reports that c-MYC over-expression is critical for MB 
progression [10, 13], we reasoned that co-targeting both 
PDGFRβ and c-MYC could maximize the suppression 
of MB progression, especially in SHH and Group 3 
MBs. On the basis of phenotypes and molecular features, 
Daoy may be regarded as a SHH tumor, while D283 
and D425 are considered as Group 4 and Group 3 MB 
tumors, respectively [14, 23–33, 64]. All 3 cell lines 
with detectable PDGFRs and c-MYC (Figure 3A) 
were used to target both PDGFRβ and c-MYC 
simultaneously using siRNAs against PDGFRβ and c-MYC, 
and also pharmacological inhibitors, SJ001 (a novel 
PDGFR inhibitor, also called cambogin) [65] and 10058-
F4 (it inhibits the c-MYC-Max interaction) [46–48]. The 
specificity and efficacy of siRNA knockdown of PDGFRβ or 
c-MYC or both were confirmed by Western blotting analysis 
(Figure 3A). The results show that blockade of PDGFRβ 
and c-MYC signaling using either RNA interference or 
pharmacological intervention inhibited both MB cell 
proliferation and migration (Figure 3B, 3D). Although 
in Figure 2D, we show that c-MYC is partially regulated 
by PDGFRβ signaling, the observation of that PDGFRβ 
signaling affected cell migration more significantly than 
proliferation, whereas c-MYC signaling mainly contributed 
to suppression of cell proliferation, indicating that PDGFRβ 
and c-MYC act on different pathways. Notably, SJ001 is 
able to inhibit both PDGFRα and PDGFRβ [65], indicating 
that PDGFRβ may have a decisive role on cell proliferation 
and migration in MB when both PDGFRs are repressed 
simultaneously. Co-targeting of PDGFRβ and c-MYC using 
either gene specific siRNAs or pharmacological inhibitors 
potentiated the effects on cell proliferation and migration, 
as shown by synergism in suppression of cell proliferation 
and migration compared to blockade of either c-MYC or 
PDGFRβ alone (Figure 3C, 3D).
Figure 3: Co-inhibition of PDGFRβ and c-MYC suppresses MB cell proliferation and migration. MB cells were transfected 
with gene-specific siRNAs for PDGFRβ and c-MYC and also with PDGFR and c-MYC specific inhibitors alone or in combination for 48 h. 
(A) Confirmation of specific gene knockdown by Western blotting analysis. β-actin was used as the loading control. (B) The effects of 
c-MYC inhibitor 10058-F4 on MB cell proliferation. (C) The effects of siRNAs and inhibitors on MB cell proliferation were determined 
using MTS. *p < 0.05, **p < 0.01 (paired t-test, sample vs. control). (D) The effects of co-inhibiting PDGFRβ and c-MYC on MB cell 
migration. Daoy cells were transfected with gene specific siRNAs for PDGFRβ and c-MYC and also with PDGFR and c-MYC specific 
inhibitors alone or in combination for 36 h. Treated cells were then detached and re-distributed in equal amounts in a 48-well plate before 
a linear wound was made. The image was captured immediately after that an artificial wound was made at 0th h and also at 24th h (Figures 
S3a, S3b). Quantified results were calculated from the images. Percentage wound closure shows the migration rate in PDGFRβKD, c-MYCKD 
or PDGFRβKDc-MYCKD cells when compared to control sample, *p < 0.05, **p < 0.01, ***p < 0.001 (paired t-test, sample vs. control).
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miR-1280 expression is regulated by PDGFRβ 
and c-MYC, and functionally important for MB 
cells
To find the common targets which are optimally 
responsible for both migration/invasion and proliferation, 
we explored the involvement of miRNAs in PDGFRα, 
PDGFRβ, and c-MYC signaling in MB cells by determining 
the miRNA profiles of Daoy cells without (Mock) and 
with knockdown of PDGFRα (PDGFRαKD), PDGFRβ 
(PDGFRβKD), c-MYC (c-MYCKD), and both PDGFRβ 
and c-MYC (PDGFRβKDc-MYCKD) using the miRCURY 
LNATM microRNA Array (6th Gen) platform. We observed 
that knockdown of PDGFRα had little effect on miRNA 
expression, while knockdown of either PDGFRβ or c-MYC 
markedly changed the miRNA profiles (Figure 4A). Among 
1497 tested miRNAs, 159 miRNAs were modulated by 
PDGFRβ (57 up-regulated and 102 down-regulated); 
125 miRNAs were altered by c-MYC (76 up-regulated 
and 49 down-regulated), and 22 miRNAs responded to 
both PDGFRβ and c-MYC. Comparative analysis of 
the respective miRNA profiles revealed that among 39 
highly regulated miRNAs, a subset of miRNAs including 
miR-1280 and miR-1260 was concordantly regulated by 
PDGFRβ and c-MYC (Figure 4A). Next we analyzed the 
expression levels of miR-1280 and miR-1260 (two highly 
regulated miRNAs by both PDGFR and c-MYC) by real-
time RT-PCR upon knockdown of PDGFRα and PDGFRβ, 
each separately or both combined, in three MB cell lines 
(Daoy, D283, and D425). The results agreed with the data 
generated by miRNA profiling analysis (Figure 4B). To 
determine the biological functions of miR-1280 and miR-
1260 in MB cells, PDGFRβKD Daoy cells were treated 
with either a miR-1280 inhibitor or a miR-1260 inhibitor, 
and cells were then analyzed for miR-1280 or miR-1260 
expression, cell proliferation, and migration. We found that 
both miR-1280 and miR-1260 inhibitors down-regulated 
the expression of miR-1280 and miR-1260 (Figure 4C, 4D), 
respectively, in PDGFRβKD Daoy cells. Notably, treatment 
with the miR-1280 inhibitor restored the cellular function 
of PDGFRβKD cells; while the miR-1260 inhibitor had less 
pronounced effects on both cell proliferation and migration. 
Thus, we selected miR-1280 for the further investigation. 
In response to miR-1280 inhibition, PDGFRβKD cells 
showed 15% and 55% increases in cell proliferation and in 
cell migration (Figure 4E, 4F), respectively. Taken together, 
these results provide a strong support that PDGFRα and 
PDGFRβ regulate different molecular downstream targets, 
resulting in distinct functional roles for MB progression.
Identification of JAG2 as a potential new MB 
therapeutic target regulated by PDGFRβ and 
c-MYC
To further understand the miRNA network 
regulated by PDGFRβ and c-MYC, we used a miRNA 
target prediction strategy as previously outlined [66, 67] 
to analyze the potential targets of the highly regulated 
miRNAs. Based on the number of potential interaction 
sites between miRNA and its potential targets, the score 
of sequence alignment at the 3’ UTR of the potential 
target gene and available literature regarding the function 
of the potential targets, we identified that JAG2 is a 
potential target regulated by miRNAs under the control 
of both PDGFRβ and c-MYC. These results suggest that 
PDGFRβ and c-MYC likely modulate genes related to 
cell proliferation and survival via certain miRNAs and 
their targets, including JAG2 as a target of miR-1280. 
To further test and validate the results obtained from 
bioinformatics aided identification of miRNA target, we 
treated MB cells with PDGFRβ and c-MYC siRNAs alone 
or in combination and then analyzed the expression levels 
of JAG2 protein by Western blotting analysis. A decrease 
in JAG2 expression occurred in MB cells lacking either 
PDGFRβ or c-MYC. An even more significant reduction 
of JAG2 protein levels was observed in MB cells lacking 
both PDGFRβ and c-MYC compared to either control or 
knockdown of PDGFRβ and c-MYC alone (Figure 5A). 
These results indicate that both PDGFRβ and c-MYC 
regulate the expression of JAG2 via miR-1280 in MB 
cells. This conclusion is further supported by the fact 
that the level of JAG2 increased markedly in the cells 
treated with a miR-1280 inhibitor compared to the control 
(Figure 5B). To further elucidate the role of JAG2 in MB 
biology, JAG2 was specifically knocked down using 
siRNAs in all three MB cell lines (Figure 5C), and its 
effects on cell proliferation and migration were analyzed 
using MTS and wound healing assay, respectively. The 
results showed that JAG2 knockdown in MB cells reduced 
cell proliferation (p < 0.01) and migration (p < 0.001) 
(Figure 5D, 5E). To determine the clinical significance 
of JAG2 in MB, we analyzed the prognostic values of 
JAG2 expression levels in 64 MB samples. We observed 
increased expression levels of JAG2 in metastatic MB 
tumors (Figure 5F, p < 0.05) and the expression levels of 
JAG2 correlated with poor prognosis outcomes (Figure 
5G, p < 0.001).
DISCUSSION
Over-expression of PDGFRs has been considered 
as a hallmark feature of MB metastasis and thus as 
therapeutic targets in high-risk MBs [10–14]. In this study, 
we found that the expression of PDGFRα and PDGFRβ 
in MBs is subgroup specific and associated with distinct 
molecular signatures; and only elevated level of PDGFRβ 
is linked with an aggressive phenotype of MB in vitro 
experiments. We present data showing that PDGFRα and 
PDGFRβ differentially regulate MB cellular functions - 
with PDGFRα limiting and PDGFRβ promoting cell 
proliferation, survival, and migration/invasion. Through 
targeting PDGFRβ and c-MYC, we revealed that the 
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Figure 4: PDGFRβ and c-MYC differentially regulate miRNA expression in MB cells. (A) Heat map represents the 
differentially regulated miRNAs by Control (Mock), PDGFRαKD, PDGFRβKD, c-MYCKD or PDGFRβKDc-MYCKD cells. The normalized log 
ratio values were used for the analysis. The clustering was performed on all samples, and the highly differentially regulated 39 miRNAs 
were selected. Each row represents a miRNA and each column represents a sample. The color scale illustrates the relative expression 
levels of miRNAs. Green color represents an expression level below the reference channel, and red color represents the expression higher 
than the reference. (B) The expression levels of miRNAs regulated by PDGFRα, PDGFRβ, and c-MYC in MB cell lines. MB cells were 
transfected with gene specific siRNAs for PDGFRα, PDGFRβ, and c-MYC alone or in combination of PDGFRβ and c-MYC for 24 h. 
p < 0.05 was considered to be statistically significant. (C) miR-1280 inhibitor suppresses miR-1280 expression in Daoy cells. PDGFRβKD 
Daoy cells were transfected with control or increasing concentrations of miR-1280 specific inhibitor using Lipofectamineltx in opti-MEM 
reduced serum medium following the manufacturer’s instruction for 4 h. The cells were then fed with equal volume of MEM medium with 
10% FBS. After 24 h, total RNA isolated was subjected to TaqMan microRNA assay to verify for specific inhibition of miRNAs. Data 
are presented as mean values (n = 3) ± standard deviation. Differences between 2 groups were analyzed using Student’s t-test. p < 0.05 
was considered to be statistically significant. (D) miR-1260 inhibitor suppresses miR-1260 expression in Daoy cells. (E) The effects of 
miR-1280 and miR-1260 on MB cell proliferation. PDGFRβKD Daoy cells were treated with control or miR-1280 inhibitor or miR-1260 
inhibitor. The effects on cell proliferation were determined by MTS assay. (F) The effects of miR-1280 and miR-1260 on PDGFRβKD Daoy 
cell migration. PDGFRβKD Daoy cells were treated with control or miR-1280 inhibitor or miR-1260 inhibitor. The treated cells were then 
detached and re-distributed in equal amounts in a 48-well plate before a linear wound was made. The image was captured immediately 
after an artificial wound was made at 0th h and also at 24th h (Figure S4a). Quantified results were calculated from the images. The treated 
samples were compared to control sample, *p < 0.05, **p < 0.01, ***p < 0.001 (paired t-test, sample vs. control).
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biological effects of PDGFRβ appear to be orchestrated 
by novel mediators including the miR-1280-JAG2 axis, 
which enhanced MB proliferation and migration in 
vitro. We further showed that the expression of JAG2 is 
correlated with the stages of MB metastasis and associated 
with a poor outcome in MB patients, indicating that JAG2 
is a novel potential target. Thus our mechanistic studies 
on PDGFRβ promoting MB growth and migration via 
miRNAs and miRNA targets provide new insight that may 
help resolve the long-standing controversy on the role of 
PDGFRs in MB.
The notion that PDGFRα and PDGFRβ contain 
well-conserved structure and display largely redundant 
functions has been documented and generally accepted. 
However, in this study, we present data showing that 
PDGFRα and PDGFRβ play distinct roles in MB cells by 
differentially regulating MB cellular functions. Notably, 
structure-function analysis of the two PDGFRs shows that 
although they share 70% homologues in the N-termini and 
80% in the C-termini of the kinase domain [68], significant 
differences exist in their ligand binding domain (31% 
identical) and a sub-domain located at the C-terminal 
region (27–28% homologues). These dissimilar structural 
features presumably can account for, at least in part, 
how the two receptors show differential ligand binding 
specificity and affinity and additionally, interaction with 
unique target protein sets to mediate starkly distinct 
functions in vitro [69] and in vivo [68, 70, 71].
Oncogenic activation of the c-MYC gene is 
commonly observed in MBs [13, 14, 72, 73] and over-
expression of c-MYC is one of the critical features of 
Group 3 MBs [25, 60]. The subset of MB patients with 
17p loss and higher levels of c-MYC is characterized by 
shorter survival [14]. Notably, majority of the MB cell 
lines established from pediatric MB patients express high 
levels of c-MYC [13, 72]. Based on our current study, the 
over-expression of c-MYC in MB could be partially due to 
abnormal PDGFR signaling because c-MYC is a PDGFRβ 
downstream target (Figure 2D). Although c-MYC 
expression is partially regulated by PDGFRβ, c-MYC 
and PDGFRβ regulate cellular functions differently, since 
PDGFRβ siRNA or inhibitor had a greater inhibitory effect 
Figure 5: Identification of JAG2 as a potential target of MB. (A) The expression of JAG2 in MB cells is regulated by PDGFRβ 
and c-MYC. MB cells were transfected with gene specific siRNAs against PDGFRβ and/or c-MYC for 48 h. Protein lysates extracted from 
treated samples were used for the expression levels of JAG2 by Western blotting. β-actin was used as a loading control. (B) The expression 
levels of JAG2 are regulated by a miR-1280 inhibitor. PDGFRβKD Daoy cells were transfected with increasing concentrations of a miR-
1280 specific inhibitor. After 48 h, protein lysates extracted were subjected to Western blotting analysis to check for change in expression 
of JAG2 protein. β-actin was used as a loading control. (C) Confirmation of specific knockdown JAG2 by Western blotting analysis. β-actin 
was used as the loading control. (D) The effects of JAG2 siRNA on MB cell proliferation. MB cells were transfected with control or JAG2 
specific siRNAs for 48 h. Cell proliferation was determined using MTS. (E) The effects of JAG2 on MB cell migration. PDGFRKD Daoy 
cells were treated with control or JAG2 siRNAs for 36 h and then detached and re-distributed in equal amounts in a 48-well plate before a 
linear wound was made. The image was captured immediately after an artificial wound was made at 0th h and also at 24th h (Supplemental 
Figure S4B). Quantified results were calculated from the images. The significance of JAG2 siRNAs on MB cell migration were analyzed 
using paired t-test, sample vs. control (*p < 0.05, **p < 0.01). (F) The expression of JAG2 in MB tissues of different stages of metastasis 
(45 patients at M0 stage, 5 patients at M1 stage, 4 patients at M2 stage, and 9 patients at M3 stage); (G) Kaplan-Meier plots of overall 
survival (OS) time according to JAG2 levels in MB patients.
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on migration, while c-MYC siRNA or inhibitor primarily 
blocked MB cell proliferation. Importantly, only blockade 
of PDGFRβ showed significant effects on limiting cell 
invasion (Figure 2C), suggesting that PDGFRβ may 
play a more critical role in MB invasion. Although our 
current data from patients with MB that high levels of 
PDGFRβ are mainly observed in SHH tumors, high 
levels of PDGFRβ also exist in other subgroups and all 
cell lines tested in this study (Figure 1D, 3A). Therefore, 
targeting both PDGFR and c-MYC might provide a 
novel therapeutic strategy for treating MB. Indeed, we 
have demonstrated that the combined inhibition of both 
PDGFRβ and c-MYC using either gene-specific siRNAs 
or pharmacological inhibitors showed additive inhibitory 
effects on both MB cell proliferation and migration 
compared to single knockdown of either PDGFRβ or 
c-MYC (Figure 3C, 3D).
MicroRNAs provide an important mechanism 
for modulating signaling pathways [74–78]. While 
analysis the PDGFR specific signatures in MB tumors, 
we noticed the results from 2 out of 5 data sets showing 
that PDGFRβ, but not PDGFRα, was associated with 
miRNA_in_cancer (Tables S2, S3). Our array knockdown 
analysis of individual PDGFRs also show that PDGFRα 
signaling has little effects on miRNA regulation in the 
tested cells (Figure 4A). Through miRNA profiling, target 
prediction and validation, we revealed that PDGFRβ and 
c-MYC may modulate MB biology via a set of highly 
regulated miRNAs (Figure 4A) and miRNA targets. 
Notably, Schopman et al. showed that miR-1280 might be 
a fragment of a tRNA based on their sequence similarity 
and annotation [79]. We first confirmed the expression 
of miR-1280 in different MB cell lines that responded to 
knockdown of PDGFRα, PDGFRβ or c-MYC. We further 
demonstrated that the miR-1280 inhibitor suppressed the 
expression of miR-1280 in MB cells (Figure 4C), and that 
this suppression had a more pronounced effect on cellular 
motility than proliferation (Figure 4E, 4F). Knockdown of 
either PDGFRβ, c-MYC alone or in combination provided 
evidence of an inverse correlation between the expression 
levels of miR-1280 and its expected target, JAG2 (Figure 
4B, 5A). The expression of JAG2 in MB cells regulated 
by miR-1280 was further confirmed in studies using a 
miR-1280 inhibitor (Figure 5B). These results support 
the notion that JAG2 is a bona fide target of miR-1280. 
Furthermore, the effects of JAG2 siRNA phenocopied the 
functional effects of the miR-1280 inhibitor on Daoy cell 
proliferation and migration in the current study. Now, we 
have direct evidence that JAG2 is involved in PDGFRβ 
and c-MYC signaling, supporting the novel PDGFRβ-c-
MYC-JAG2 regulatory axis in MB growth and migration 
(Figure 6). Our findings are in line with a recent paper 
indicating that Notch signaling and c-MYC signaling 
transduction are linked in MBs [80]. However, it further 
extends this report by suggesting an upstream regulatory 
role PDGFRβ in this signaling network and delineating 
that miR-1280 has an important role in the transcriptional 
regulation of JAG2. Further, here we demonstrate for the 
first time that JAG2 is regulated by PDGFRB and c-MYC 
and there is an immediate functional impact of JAG2 
abrogation in MBs. Given that c-MYC is a well-known 
driver of oncogenesis in many models and cancer types, 
and that JAG2 is a c-MYC-regulated gene [81], the 
PDGFRβ-c-MYC-JAG2 pathways would be a logical and 
expected mechanism of MB carcinogenesis.
JAG2 is a transmembrane glycoprotein that binds 
to notch receptors regulating cell proliferation and 
differentiation in both normal and pathological conditions 
[50, 82, 83]. The significance of Notch signaling in MB 
has been demonstrated by employing inhibitors designed 
to suppress various key regulators playing important 
roles in the Notch pathway, wherein accompanying 
changes manifested as a reduction in cell proliferation 
and increase in apoptosis were observed [51–53], thus 
implicating Notch signaling as a target that may constitute 
an additional promising treatment strategy for MB 
patients. By inference, therefore, it may be proposed 
that co-targeting of Notch and PDGFR signaling should 
constitute a more promising effective therapeutic modality 
for MB, particularly since previous data show that Notch1 
Figure 6: Schematic representation of pathways promoting MB progression by PDGFRβ and c-MYC, and the axis 
connecting PDGFRβ to JAG2, through c-MYC and miR-1280. 
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inhibition may not be sufficiently robust to achieve tumor 
control in a small cohort of pre-treated, relapsed MBs [84].
In conclusion, our results demonstrate that 
PDGFRβ, not PDGFRα, plays an essential role in MB 
biology. The promoting of MB progression by PDGFRβ 
and c-MYC could through their several downstream 
effectors, among which a set of miRNAs, e.g., miR-
1280, and concomitantly up-regulates the expression 
of tumorigenic factors, e.g., JAG2 are important 
contributors. As the existence of PDGFRβ and c-MYC 
expression MBs, simultaneous inhibition of PDGFRβ and 
c-MYC signaling in MB cells synergistically suppresses 
both cell migration and cell proliferation. We further 
revealed that the expression of JAG2 is linked with MB 
metastasis and patients with a poor outcome. Finally, our 
results proffer the therapeutic tenet that co-targeting of 
PDGFRβ and c-MYC, or PDGFRβ and Notch signaling 
may represent novel therapeutic strategies for the 
treatment of MB.
MATERIALS AND METHODS
Analysis of PDGFRs, c-MYC, and JAG2 
expression in primary MB
Using the R2 software (http://r2.amc.nl), we 
analyzed candidate gene expression levels in primary 
MBs and normal cerebellar samples, and correlated 
gene expression patterns with subgroup annotation to a 
recently published gene expression profiling study [29, 
32, 57–59]. The specific pathways associated with the 
expression of PDGFRα, PDGFRβ, and c-MYC in MBs 
were analyzed in 5 available complete data sets in the 
R2 database using the KEGG pathway finder option. The 
pathways that show significant (p ≤ 0.01, chi-squared 
test) enrichment based on the genes co-expressed with 
PDGFRs were identified and specific pathways found in 
at least 2 of 5 data sets were ordered [29, 32, 33, 59, 60]. 
In addition to standard descriptive and graphical analyses, 
qualitative and quantitative association of variables 
was also evaluated by one-way ANOVA or the Mann-
Whitney test, respectively. Survival was measured from 
the time of initial diagnosis to the date of death or the 
date of last follow up. Survival distribution was estimated 
according to the Kaplan-Meier method using optimal 
cut-off selection and log-rank statistics with Bonferroni 
based multiple testing corrections. P-values < 0.05 were 
considered to be statistically significant.
Cell culture
Human MB cell lines, Daoy and D283 were 
purchased from American Type Culture Collection and 
D425 cells were a gift from Dr. Darell D. Bigner [85]. 
Daoy and D283 cells were maintained in modified Eagle’s 
medium (MEM) containing 10% fetal bovine serum 
(FBS), 2 mM non-essential amino acids and 5 mM sodium 
pyruvate. D425 cells were maintained in Zinc-rich MEM 
medium containing 10% FBS and cultured in a 5% CO2 
incubator at 37°C.
RNA interferences
PDGFRα siRNA duplex (5′-GGAGGAUG 
AUGAUUCUGCCAUUAUA-3′ ), PDGFRβ siRNA duplex 
(5′-UCACGGAAAUAACUGAGAUCACCAU-3′ ), and 
control (mock) siRNA duplex (5′-ACAUCACGUACGCG 
GAAUACUUCGA-3′) were obtained from Invitrogen. 
JAG2 siRNA, a pool of 4 siRNA duplexes 
(5′-GCAAGGAAGCUGUGUGUAA-3′, 5′-GCGUGUGC 
CUUAAGGAGUA-3′, 5′-GAACGGCGCUCGCUGC 
UAU-3′, 5′-GGUCGUACUUGCACUCACA-3′ ) were 
purchased from Dharmacon. c-MYC siRNA 
is a pool of 3 different siRNA duplexes (5′- 
CCCAAGGUAGUUAUCCUUAtt-3′, 5′-GGAAACGAC 
GAGAACAGUUtt-3′, and 5′-CCUGAGCAAUCA 
CCUAUGAtt-3′ ) were purchased from Santa 
Cruz. Transfection of siRNA was performed using 
Lipofectamine™ (Invitrogen) according to the company’s 
instructions.
Cell proliferation
Cells (2 × 104/well) were incubated in 70% MEM 
with 10% FBS, 30% Opti-MEM with 15 pM siRNA, or 
miRNA inhibitor (Applied Biosystems) and 0.25 μl/well 
of Lipofectamine (Invitrogen) in 96-well plates. For the 
experiments using inhibitors, cells were treated with either 
SJ001 (cambogin, 5 μM) [65] or 10058-F4 (an inhibitor 
that disrupts the c-MYC-Max interaction ) [45–47] 
(Calbiochem) at various concentration as indicated in the 
figures. At 48 h post-treatment, cell proliferation rates 
were determined using a MTS assay (Promega).
Lactate dehydrogenase (LDH) based cell death 
index
Cells (2 × 104/well) were placed in MEM without 
penicillin and streptomycin a day before transfection in 
24-well plates. After 48 h of siRNA transfection, culture 
media were harvested for assessment of released LDH 
using an LDH based toxicology assay kit (Sigma).
RT-PCR and western blotting
Real-time RT-PCR and Western blotting were 
performed as described [69]. The antibodies were purchased 
from various manufacturers: anti-human PDGFRα rabbit 
antibody (Santa Cruz), anti-human PDGFRβ rabbit antibody 
(Epitomics), anti-human PDGFRα mouse neutralizing 
antibody (R&D), anti-human PDGFRβ goat neutralizing 
antibody (R&D), c-MYC rabbit antibody (Sigma), JAG2 
rabbit antibody (Cell Signaling), β-actin mouse antibody 
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(Sigma), secondary rabbit HRP-conjugated antibody (Bio-
Rad), secondary mouse HRP-conjugate antibody (Sigma).
Invasion and wound healing assay
Boyden chamber 24-well invasion assay kit was 
purchased from Calbiochem. Invasion assays were 
performed as previously described [69]. Wound healing 
assays were used to measure the rate of cell migration 
[86]. Daoy cells were treated with siRNA, or inhibitor 
as indicated in the Figures. Equal amount of scrambled 
siRNA or solvent served as a control. At 36 h, cells were 
detached, and equal number of cells was re-distributed in 
a 48-well plate. After 48 h incubation, an artificial wound 
was made using a 100 μl pipette tip by scraping across the 
bottom of the well. The medium was changed to remove 
all detached cells. Movement of cells into the wound 
area was captured by taking images at 0 and 24 h using a 
phase-contrast microscope (Olympus). Migration rates in 
percentage were calculated by comparing the width of the 
wound at 0 and 24 h in each sample against control cells. 
Wound healing assay was not performed on D283 and 
D425 cells as they are half adherent/half suspension cells. 
Experiments were performed in triplicate. The results are 
presented as percentage for wound healing.
MicroRNA (miRNA) profiling
Control shRNA, PDGFRα-shRNA and PDGFRβ-
shRNA plasmids were prepared using a vector (pRNAT-
CMV3.2/Neo) from GenScript. The plasmids were 
introduced into Daoy cells followed by G418 selection. 
The control cells (harboring a mask control shRNA vector) 
and PDGFRβKD cells were used to prepare c-MYCKD and 
PDGFRβKDc-MYCKD cells, respectively, using c-MYC 
specific siRNA. Total RNAs were isolated from control, 
PDGFRα, PDGFRβKD, c-MYCKD, and PDGFRβKD 
c-MYCKD cells using the miRCURYTM RNA isolation 
kit (Exiqon) following the manufacturer’s protocol. 
NanoDrop 1000 spectrophotometer (Thermo Scientific) 
and agarose gel electrophoresis were used to assess the 
quality of the RNA isolated. The samples were labeled 
using the miRCURY LNATM microRNA Hi-Power 
Labeling kit Hy3TM/Hy5TM (Exiqon) and hybridized on the 
miRCURY LNATM microRNA Array (6th Gen, Exiqon). 
Duplicate samples for each cell type were applied to the 
array analysis. The quantified signals were normalized 
(background corrected) using the global Lowess regression 
algorithm and the highly differentially regulated miRNAs 
were selected and presented in the heat map.
Determination of miRNAs by Taqman PCR
Total RNA was isolated using TRI reagent (Sigma). 
One μg of total RNA was used to prepare miRNA specific 
cDNA using TaqMan® microRNA reverse transcription kit 
(Applied Biosystems). One μl of this cDNA was used to 
perform qRT-PCR using 20x TaqMan® MicroRNA assay 
along with TaqMan Universal PCR master mix (Applied 
Biosystems) to validate the regulated miRNAs in MB 
cells. RNU6B was chosen as an endogenous control. 
Experiments were performed in duplicate. PCR was 
performed using the following program: initial enzyme 
activation at 95°C for 10 min, denaturation at 95°C for 
15s followed by annealing/extension at 60°C for 1 min 
for 40 cycles. Fold change obtained from Ct values using 
2–ΔΔ Ct methodology [87] was converted into logarithmic 
base 2 for statistical analysis. p < 0.05 was considered to 
be statistically significant.
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